TLDR
- CNC shares plunged 14% on Tuesday, posting the weakest performance among all S&P 500 components
- Management projects ACA membership will decline to 3.5 million by Q1’s close, down from 5.5 million in December
- Adjusted EPS guidance of more than $3 for 2026 remains unchanged
- Mizuho lowered its price objective from $47 to $41 while keeping its Neutral stance
- Medicare Advantage profitability continues to lag, with negative margins expected to persist into 2026
Investors holding Centene shares experienced another difficult session on Tuesday. The managed care company saw its stock price collapse 14% following CEO Sarah London’s presentation at the Barclays Global Healthcare Conference, where her enrollment outlook triggered selling pressure.
During her remarks to conference participants, London confirmed that Centene’s three primary business segments continue tracking toward 2026 targets. The executive maintained the company’s adjusted earnings projection of more than $3 per share — aligning precisely with the $3 consensus from FactSet’s analyst survey.
Yet the market reaction was swift and negative. The unchanged guidance provided no positive catalyst, and market participants focused squarely on membership trends.
Management now forecasts Q1 will close with 3.5 million ACA marketplace enrollees, representing a sharp decline from the 5.5 million reported in December. Current February data shows 3.6 million members.
London indicated the company had forecasted overall market contraction “somewhere between the high teens and the mid-thirties” on a percentage basis. She noted Centene would likely “land at the higher end of that and possibly higher than the top end of that.”
The CEO explained that strategic pricing adjustments implemented at year-start contributed to the membership decline, as the company chose to emphasize profitability enhancement rather than enrollment expansion.
Medicare Advantage Still a Drag
The Medicare Advantage segment remains a profitability challenge for Centene. This business line posted negative margins throughout 2025 and will likely stay marginally below break-even during 2026, with management targeting neutral profitability by 2027.
Another factor weighing on investor sentiment is the pending final rate announcement from the Centers for Medicare and Medicaid Services, scheduled for release by April 6. The Trump administration’s earlier proposal to maintain essentially flat Medicare rates for 2027 created headwinds for Centene and industry competitors.
London mentioned the company filed detailed feedback with CMS regarding the Advance Rate Notice and voiced optimism that final rates would better account for current medical cost inflation affecting the broader sector.
Analyst Reaction
Mizuho responded immediately following the presentation. The research firm reduced its Centene price objective to $41 from $47 while maintaining its Neutral recommendation.
Mizuho highlighted worries surrounding health insurance exchange attrition and specialty pharmacy cost trajectories. The analyst team indicated it would employ a more cautious valuation framework until achieving better visibility into the ultimate scale of membership losses.
Truist Securities adopted a more constructive stance, preserving its Buy recommendation with a $49 price objective, pointing to profitability improvement potential and executive team conviction. Cantor Fitzgerald maintained its Neutral recommendation and $41 target, characterizing the 2026 operating landscape as difficult.
For perspective, Centene has declined 9.7% during 2026, compared with a 0.7% retreat for the S&P 500 benchmark.
The shares have demonstrated relative resilience versus certain industry counterparts. Molina Healthcare has fallen 17% year-to-date, Elevance Health has dropped 18%, and UnitedHealth Group has declined 14%.
Centene’s fourth quarter 2025 results delivered an adjusted diluted loss per share of $1.19, moderately outperforming the anticipated $1.22 loss. Total revenue reached $49.73 billion, surpassing the $48.39 billion projection.
InvestingPro calculates Centene’s fair value at $62.11, while the analyst community projects full-year 2026 EPS of $3.05.
